AECOPD

The Lundquist Institute Receives $2.6 Million Grant from U.S. Army Medical Research Acquisition Activity to Develop Wearable Biosensors

Retrieved on: 
Donnerstag, April 25, 2024
UCLA, Mortality, Patient, Lower respiratory tract infection, Blood, Health, CRP, Death, Partnership, Doctor of Philosophy, Research, COPD, TLI, Electronics, Conditional sentence, AECOPD, Hospital, Perspiration, Infection, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.

Key Points: 
  • Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.
  • The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA.
  • The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).
  • COPD affects approximately 16 million Americans and is the third leading cause of death globally.

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

Retrieved on: 
Mittwoch, Februar 23, 2022
Accelerator Network, Risk, Conditional sentence, CDC, Virus, Chronic obstructive pulmonary disease, Education, Awareness, ENA, COVID-19, Severe acute respiratory syndrome coronavirus 2, Chronic cough, NTM, Incidence, Infection, Therapy, Rhinovirus, Partnership, Human, AECOPD, Post-exposure prophylaxis, Interview, Fever, Disease, Mark (given name), Adoption, Epithelium, CEO, Degenerative disease, Respiratory tract, Twitter, Efficiency, Mucus, Fatigue, LinkedIn, Hospital, Patient, Digital health, Bronchiectasis, GLOBE, Mid-Tertiary ignimbrite flare-up, Death, Asthma, Respiratory disease, RSV, Foundation, Chronic lung disease, Nasal mucosa, Vaccine, Pharmaceutical industry, H1N1, COPD

SYDNEY, Australia and MIAMI, Feb. 23, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral infections, including COVID-19 in populations at-risk of complications, and the COPD Foundation, a not-for-profit organization focused on improving the lives of those affected by COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, announced a partnership to develop INNA-051 in people with chronic lung diseases.

Key Points: 
  • Respiratory virus infections, especially rhinovirus (the common cold), respiratory syncytial virus (RSV), and influenza, are related to worsening of chronic lung conditions, including chronic obstructive pulmonary disease (COPD) and asthma.
  • We are excited to partner with ENA Respiratory to advance the development of INNA-051, said Ruth Tal-Singer, Ph.D., COPD Foundation President & Chief Scientific Officer.
  • The expertise of the COPD Foundation and the shared commitment of the Foundation and ENA Respiratory to patient-centred drug development will allow the INNA-051 clinical program to progress with maximum efficiency.
  • We are thrilled to partner with the COPD Foundation to support the clinical development of INNA-051 in chronic lung diseases.

Nanomix Announces UK MHRA Registration for New Point of Care System

Retrieved on: 
Mittwoch, Dezember 8, 2021
Technology, Mobile, Wireless, Medical Devices, Software, Practice Management, Biotechnology, Managed Care, Health, General Health, U.S. Securities and Exchange Commission, Medication, Forward-looking statement, AECOPD, Company, Acute bronchitis, Health, C-reactive protein, Hospital, OTC, Pneumonia, Growth, Security (finance), Patient, CAP, Urinary tract infection, Decision-making, Biomarker, Industry, Chronic obstructive pulmonary disease, PCT, Health care, LAC, CE marking, Corporation, Emergency department, Time, MHRA, Sepsis, CRP, United Kingdom, Elab, Medical imaging, the Nanomix eLab system, the Nanomix eLab S1 Panel Cartridge, Nanomix Corporation, THE NANOMIX ELAB SYSTEM, THE NANOMIX ELAB S1 PANEL CARTRIDGE, NANOMIX CORPORATION

This registration is an important step in accelerating the introduction and availability of Nanomix products to markets and patients throughout the United Kingdom.

Key Points: 
  • This registration is an important step in accelerating the introduction and availability of Nanomix products to markets and patients throughout the United Kingdom.
  • Timely diagnostics, by the bedside, are targeted to improve treatment and transition of care decisions in both Point-of-Care and Hospital settings, commented John Hardesky, Chief Commercial Officer of Nanomix.
  • The Nanomix eLab is a mobile, hand-held immunoassay and chemistry diagnostic system.
  • The Nanomix eLab S1 Panel Cartridge has received CE Mark and MHRA Registration.